gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 08 Dec 2016.

Purinergic receptor P2Y, G-protein coupled, 12

P2Y12, platelet ADP receptor
The product of this gene belongs to the family of G-protein coupled receptors. This family has several receptor subtypes with different pharmacological selectivity, which overlaps in some cases, for various adenosine and uridine nucleotides. This receptor is involved in platelets aggregation, and is a potential target for the treatment of thromboembolisms and other clotting disorders. Two transcript variants encoding the same isoform have been identified for this gene. [provided by RefSeq, Jul 2008] (from NCBI)
Papers on P2Y12
Roles of purinergic receptor P2Y, G protein-coupled 12 in the development of atherosclerosis in apolipoprotein E-deficient mice.
GeneRIF
Liu et al., Shanghai, China. In Arterioscler Thromb Vasc Biol, 2012
P2Y12 modulates atherogenesis, at least in part by augmenting inflammatory cell recruitment via regulation of platelet alpha-granule release.
Fractalkine activates a signal transduction pathway similar to P2Y12 and is associated with impaired clopidogrel responsiveness.
GeneRIF
Schäfer et al., Hannover, Germany. In Arterioscler Thromb Vasc Biol, 2012
increased fractalkine levels are associated with decreased endogenous platelet inhibition and impaired response to P2Y12 inhibition with clopidogrel.
Arrestin scaffolds NHERF1 to the P2Y12 receptor to regulate receptor internalization.
GeneRIF
Mundell et al., Bristol, United Kingdom. In J Biol Chem, 2012
Findings suggest a novel model by which arrestin can serve as an adaptor to promote NHERF1 interaction with a GPCR to facilitate effective NHERF1-dependent receptor internalization.
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.
GeneRIF
INNOVATE-PCI Investigators et al., Edmonton, Canada. In Circ Cardiovasc Interv, 2012
In patients undergoing nonurgent percutaneous coronary intervention intravenous/oral P2Y12 inhibitor elinogrel did not significantly increase thrombolysis in myocardial infarction or bleeding.
Combined blockade of ADP receptors and PI3-kinase p110β fully prevents platelet and leukocyte activation during hypothermic extracorporeal circulation.
GeneRIF
Straub et al., Tübingen, Germany. In Plos One, 2011
Combined blockade of P2Y12, P2Y1 and PI3-kinase p110beta fully prevents platelet and leukocyte activation during hypothermic extracorporeal circulation.
share on facebooktweetadd +1mail to friends